Le Lézard
Classified in: Science and technology
Subjects: Photo/Multimedia, Survey, Economic News/Analysis

Global Dealmakers on the Hunt for Growth in 2022, Datasite Survey Finds


Though most global dealmakers expect deal activity to increase over the next 12 months, they also expect inflation, supply chain issues and environmental, social and governance (ESG) risks to be biggest obstacles to getting deals done in 2022. This is according to a new survey from Datasite, a leading SaaS-based technology provider for global mergers and acquisitions (M&A) professionals.

Almost half (48%) of the 600 global dealmakers surveyed said they expect deal volume to climb higher in 2022 compared to this year's record levels, which have been fueled by favorable interest rates and ready access to capital. When it comes to targeting potential transactions, 32% of global dealmakers said organic growth potential will be the most important evaluation consideration, ahead of revenue or cost considerations. Of the M&A opportunities dealmakers expect to see the most in 2022, 22% cited larger acquisitions as the top pick, despite increased antitrust scrutiny and ahead of joint ventures and partnerships (19%) and debt-like investments (16%).

"2021 was all about transformational deals with many organizations turning to technology and combining with other companies to ensure their competitiveness," said Rusty Wiley, CEO of Datasite. "No doubt that will continue in the new year, especially as companies continue to future-proof their businesses. There will also be opportunities to invest in growth, which can include divesting non-performing businesses or acquiring new businesses that offer access to new products, services, capabilities or markets. This may apply, especially, to deals in the consumer and industrial sectors, where we are already seeing rising activity in the number of new projects on our platform."

In fact, when it comes to specific transaction types in 2022, global dealmakers said they expect to see more restructurings (31%), refinancings and debt financings (27%), and joint ventures and partnerships (27%) compared to 2021.

Inflation, Supply Chain and ESG are biggest deal blockers in 2022

Inflation impacted deals in 2021 and is expected to again be one of the biggest deal breakers in 2022. More than 70% of global dealmakers said inflation affected a deal they had worked on in 2021, by changing company operating assumptions (33%), affecting deal valuations (26%), or ultimately causing a deal to fall apart (17%). In 2022, in addition to inflation and other macroeconomic issues such as GDP growth and unemployment, global dealmakers expect ESG risks, supply chain challenges and labor shortages to be the top risks to sink deals. However, the degree of concern varies based on location. In the US, dealmakers are most concerned about ESG risks (20%) and macroeconomic concerns (17%), while UK dealmakers see supply chain constraints (19%) and labor shortages (17%) as the most threatening, and EU dealmakers are most troubled by macroeconomic concerns (21%) and ESG risks (16%).

Technology central to dealmaking in 2022

"Technology will continue to be vital to dealmakers so that they can best manage their M&A processes, including conducting complex due diligence activities so their deals can reach successful outcomes," said Wiley. "With deal activity expected to continue at the same rate or higher next year, AI-powered tools can increase their capacity to manage a higher volume of transactions, freeing up dealmakers to focus on higher value tasks."

Indeed, the top 2021 strategy global dealmakers used most to counterbalance bandwidth constraints was technology (31%), ahead of asking employees to take on more responsibility (25%), moving people across practice areas to fill gaps (24%) and turning away deals (18%). Dealmakers' reliance on technology and digital tools may also help them to spend more time with family, which they cited as a top priority in 2022.

Spurred by high valuations, dealmakers in 2021 became more selective

Across the world, dealmakers were more selective in the deals they chose to move forward with in 2021, citing high valuations as the main reason, followed by macroeconomic concerns and bandwidth constraints. Additionally, a hefty 78% of global dealmakers said supply chain concerns impacted deals on which they worked in 2021. Of the challenges supply chain problems created, dealmakers cited "changed valuations" as the top concern (24%), followed by "forced a restructuring or divestiture" (19%), "caused a deal to fall apart" (17%) or "spurred an acquisition" (15%). Just 22% said supply chain problems didn't impact their deals at all in 2021.

To learn more about Datasite, please visit: www.datasite.com

Notes for editors

Datasite surveyed 600 US, UK and EU-based dealmakers, director level and above, involved in corporate development, banking, consulting, accounting, private equity and legal in November 2021.

About Datasite

Datasite is a leading SaaS provider for the M&A industry, empowering dealmakers around the world with the tools they need to succeed across the entire deal lifecycle. For more information, visit www.datasite.com


These press releases may also interest you

at 21:17
Report with market evolution powered by AI - The global model kits for hobbyists market size is estimated to grow by USD 219 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.65%  during the forecast...

at 21:17
Report on how AI is driving market transformation - The global crowdfunding market size is estimated to grow by USD 540.1 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  20.5%  during the forecast period....

at 20:55
NovaQuant Quantitative Think Tank Center continues to set new standards in the financial sector through its partnerships with top-tier financial institutions and academic organizations. These strategic alliances, aimed at enhancing...

at 20:50
RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment,...

at 20:31
GCCL(Global Clinical Central Lab), a leading Korean clinical trial sample analysis company, reinforced its position in the global market by receiving Frost & Sullivan's 2025 Best Practices...

at 20:15
Vecima Networks Inc. ("Vecima" or the "Company") announced today that its second quarter financial results will reflect impacts related to adjustments in the timing of some of its largest customers' cable and fiber upgrades, as well as certain...



News published on and distributed by: